Embla Medical Hf S/Adr (OSSUY) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

At this time, I would like to welcome everyone to this EMBLA Medical Q2 2026 conference call. Today's call is being recorded. If you have any objections, please disconnect at this time. All participants will be on listen only mode throughout the presentation, and afterwards, there'll be a question and answer session. I would now like to introduce President and CEO Sveinn Solvason and CFO Arna Sveinsdottir. Sveinn, over to you. Thank you very much. Good morning and welcome to EMPLA Medical's conference call to review our second quarter 2026 results. I'm Sveinn Solvason, President and CEO of EMPLA Medical. Joining me today are our Chief Financial Officer Anna Sveinsdottir and our Head of Investor Relations Klaus Sindahl. The presentation will take approximately 15 minutes followed by a Q&A session. If you please turn to the next slide. The first half of 2026 was strong. We delivered good organic growth, an increase in profitability, and solid free cash flow. Sales in the second quarter were $259 million, corresponding to 11% reported growth and 6% organic growth. Prosthetics and neuro-orthotics continued to do very well, with double-digit growth in the quarter. This was driven by strong execution, good volume growth in mainly EMEA and APAC, and contributions from recently launched products. Raising in support grew at a more modest pace and patient care declined, but we're seeing very encouraging progress. EBITDA margin was strong at 22% for the quarter. This was supported by the good performance in prosthetics and neuro orthotics, continued cost discipline and a net US tariff refund of around $3 million. Net profit was strong, increasing by 39% and this was mainly due to strong operating results and favorable movements in net financial expenses. During the second quart...